Eltrombopag For Immune Thrombocytopenic Children in a Single Region

LEBLEBİSATAN G., KILINÇ Y., Cil M., Sasmaz I., Ozkan A.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, vol.34, no.4, pp.707-710, 2018 (SCI-Expanded) identifier identifier identifier


Objective Child patients of chronic thrombocytopenic purpura with severe and resistant thrombocytopenia were evaluated to observe whether their clinical or laboratory states improve by one of the thrombomimetic therapeutic agent called Eltrombopag as in adults in a single center of different country from previous studies. Materials and Methods Nineteen patients with chronic immune thrombocytopenia were treated with Eltrombopag to dose in international guidelines. Results Approximately half (11/19:58%) of the patients benefitted from the treatment with Eltrombopag either by an increase of platelet levels at safe levels with a decrease in the frequency of bleedings which needed rescue treatment. Conclusion Thrombomimetic treatment options have strengthened the clinician's hand where the regular treatment options became insufficient.